[go: up one dir, main page]

CA2279326A1 - Utilisation du 1-[4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyrid-1yl]-2-(6,7-dimethoxynapht-2-yl)ethane pour la preparation de medicaments destines aux traitements de troubles cerebraux et neuronaux - Google Patents

Utilisation du 1-[4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyrid-1yl]-2-(6,7-dimethoxynapht-2-yl)ethane pour la preparation de medicaments destines aux traitements de troubles cerebraux et neuronaux Download PDF

Info

Publication number
CA2279326A1
CA2279326A1 CA002279326A CA2279326A CA2279326A1 CA 2279326 A1 CA2279326 A1 CA 2279326A1 CA 002279326 A CA002279326 A CA 002279326A CA 2279326 A CA2279326 A CA 2279326A CA 2279326 A1 CA2279326 A1 CA 2279326A1
Authority
CA
Canada
Prior art keywords
treatment
disorders
cerebral
dementia
tetrahydropyrid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002279326A
Other languages
English (en)
French (fr)
Inventor
Tiziano Croci
Jacqueline Fournier
Umberto Guzzi
Costantino Palmieri
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2279326A1 publication Critical patent/CA2279326A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
CA002279326A 1997-02-03 1997-02-03 Utilisation du 1-[4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyrid-1yl]-2-(6,7-dimethoxynapht-2-yl)ethane pour la preparation de medicaments destines aux traitements de troubles cerebraux et neuronaux Abandoned CA2279326A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/FR1997/000202 WO1998033502A1 (fr) 1997-02-03 1997-02-03 Utilisation du 1-[4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyrid-1yl]-2-(6,7-dimethoxynapht-2-yl)ethane pour la preparation de medicaments destines aux traitements de troubles cerebraux et neuronaux

Publications (1)

Publication Number Publication Date
CA2279326A1 true CA2279326A1 (fr) 1998-08-06

Family

ID=9502506

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002279326A Abandoned CA2279326A1 (fr) 1997-02-03 1997-02-03 Utilisation du 1-[4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyrid-1yl]-2-(6,7-dimethoxynapht-2-yl)ethane pour la preparation de medicaments destines aux traitements de troubles cerebraux et neuronaux

Country Status (11)

Country Link
EP (1) EP0954311A1 (cs)
JP (1) JP2001511141A (cs)
AU (1) AU1607397A (cs)
CA (1) CA2279326A1 (cs)
CZ (1) CZ275399A3 (cs)
EE (1) EE9900332A (cs)
HU (1) HUP0000767A3 (cs)
IL (1) IL130994A0 (cs)
IS (1) IS5117A (cs)
TR (1) TR199901722T2 (cs)
WO (1) WO1998033502A1 (cs)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6272180B1 (en) * 1997-11-21 2001-08-07 Sharp Laboratories Of America, Inc. Compression and decompression of reference frames in a video decoder

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2662355B1 (fr) * 1990-05-22 1994-11-10 Sanofi Sa Utilisation de la 1-[2-(2-naphtyl)ethyl]-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine pour la preparation de medicaments destines au traitement de troubles cerebraux et neuronaux.
FR2662442A1 (fr) * 1990-05-23 1991-11-29 Midy Spa Trifluoromethylphenyltetrahydropyridines n-substituees procede pour leur preparation, intermediaires du procede et compositions pharmaceutiques les contenant.
US5618822A (en) * 1990-05-23 1997-04-08 Sanofi N-substituted trifluoromethylphenyltetrahydropyridines, process for the preparation thereof, intermediates in said process and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
IL130994A0 (en) 2001-01-28
IS5117A (is) 1999-07-15
TR199901722T2 (xx) 2000-08-21
CZ275399A3 (cs) 1999-12-15
AU1607397A (en) 1998-08-25
JP2001511141A (ja) 2001-08-07
HUP0000767A3 (en) 2000-10-30
EP0954311A1 (fr) 1999-11-10
HUP0000767A2 (hu) 2000-09-28
WO1998033502A1 (fr) 1998-08-06
EE9900332A (et) 2000-02-15

Similar Documents

Publication Publication Date Title
EP0458696B1 (fr) Utilisation d'une 1-(2-naphtyléthyl)-4-(3-trifluorométhylphényl)-1,2,3,6-tétrahydropyridine pour la préparation de médicaments destinés au traitement de troubles cérébraux et neuronaux
EP0369887B1 (fr) Utilisation de trifluorométhylphényltétrahydropyridines pour la préparation de médicaments destinés à combattre les troubles anxio-dépressifs
EP0866704B1 (fr) Utilisation de la 1-(2-napht-2-ylethyl)-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine pour la preparation de medicaments destines au traitement de la sclerose laterale amyotrophique
WO1999058117A1 (fr) Utilisation de composes reduisant l'apoptose
FR2501506A1 (fr) Compositions pharmaceutiques a action anorexigene contenant des derives de la tetrahydropyridine
WO2000064423A2 (fr) Utilisation du saredutant et de ses sels pharmaceutiquement acceptables dans le traitement ou la prevention des troubles de l'humeur d'adaptation et de l'anxiete-depression
EP1133296B1 (fr) Nouvelle application therapeutique de la nicergoline
CA2279326A1 (fr) Utilisation du 1-[4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyrid-1yl]-2-(6,7-dimethoxynapht-2-yl)ethane pour la preparation de medicaments destines aux traitements de troubles cerebraux et neuronaux
EP1030671A1 (fr) Association de principes actifs, notamment de tetrahydropyridines et d'agents inhibiteurs de l'acetylcholinesterase, pour le traitement de la demence senile du type alzheimer
CA2361988A1 (fr) Utilisation de la tianeptine pour l'obtention de medicaments destines au traitement des pathologies de la neurodegenerescence
EP0950049B1 (fr) Diphenylalkyl-tetrahydropyridines, procede pour leur preparation et composition pharmaceutique les contenant
EP0615755B1 (fr) Utilisation de dérivés de la tétrahydropyridine pour la préparation de médicaments cardioprotecteurs
EP0851856B1 (fr) Derives d'indole comme analogues melatonergiques
EP0950048B1 (fr) 1-phenylalkyl-1,2,3,6-tetrahydropyridines pour le traitement de la maladie d'alzheimer
EP0489640B1 (fr) Utilisation de phényléthanolaminotétralines pour la préparation de médicaments antidépressifs et anti-stress
WO1999040911A1 (fr) Utilisation de composes selenies dans la prevention et le traitement de la maladie d'alzheimer
EP0786988B1 (fr) Utilisation d'antagonistes des recepteurs nk1 pour la preparation de medicaments a action cardioregulatrice
FR2639227A1 (fr) Utilisation de derives du chromane pour le traitement des etats depressifs
EP0950053B1 (fr) Nouveaux derives de benzoylalkyl-1,2,3,6-tetrahydropyridines
EP1237552B1 (fr) Association de lumilysergol et riluzole pour la prevention et/ou le traitement de maladies motoneuronales
EP1133297B1 (fr) Nouvelle application therapeutique de la 1, 6- dimethyl-8beta-hydroxymethyl -10alpha- methoxyergoline
FR2771007A1 (fr) Association de principes actifs pour le traitement de la demence senile du type alzheimer
FR2527077A1 (fr) Nouveau medicament a base d'un anti-depresseur et d'un alcaloide ergopeptidique
EP0475844A1 (fr) Utilisation de N-(1-hexahydroazepinylalkyl) acétamides dans la préparation des médicaments destinés au traitement des troubles de la transmission cholinergique

Legal Events

Date Code Title Description
FZDE Discontinued